Light-Induced Radiosynthesis of
Animals
Antibodies, Monoclonal
/ chemistry
Azepines
/ chemistry
Cell Line, Tumor
Chemistry Techniques, Synthetic
Deferoxamine
/ chemistry
Half-Life
Humans
Light
Mice
Positron-Emission Tomography
/ methods
Proto-Oncogene Proteins c-met
/ metabolism
Radiochemistry
Radioisotopes
/ chemistry
Tissue Distribution
Zirconium
/ chemistry
89Zr
MetMAb
antibodies
hepatocyte growth factor receptor (c-MET)
immuno-PET
onartuzumab
photoradiosynthesis
Journal
Journal of nuclear medicine : official publication, Society of Nuclear Medicine
ISSN: 1535-5667
Titre abrégé: J Nucl Med
Pays: United States
ID NLM: 0217410
Informations de publication
Date de publication:
07 2020
07 2020
Historique:
received:
04
10
2019
accepted:
21
11
2019
pubmed:
12
1
2020
medline:
29
12
2020
entrez:
12
1
2020
Statut:
ppublish
Résumé
Methods that provide rapid access to radiolabeled antibodies are vital in the development of diagnostic and radiotherapeutic agents for PET or radioimmunotherapy. The human hepatocyte growth factor receptor (c-MET) signaling pathway is dysregulated in several malignancies, including gastric cancer, and is an important biomarker in drug discovery. Here, we used a photoradiochemical approach to produce
Identifiants
pubmed: 31924725
pii: jnumed.119.237180
doi: 10.2967/jnumed.119.237180
pmc: PMC7383074
doi:
Substances chimiques
Antibodies, Monoclonal
0
Azepines
0
Radioisotopes
0
Zirconium
C6V6S92N3C
Proto-Oncogene Proteins c-met
EC 2.7.10.1
Deferoxamine
J06Y7MXW4D
onartuzumab
MS1J9720WC
Zirconium-89
NTM296JU95
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1072-1078Informations de copyright
© 2020 by the Society of Nuclear Medicine and Molecular Imaging.
Références
Chem Commun (Camb). 2019 Feb 19;55(16):2257-2260
pubmed: 30604798
Nat Protoc. 2012 May 17;7(6):1138-44
pubmed: 22596226
Org Biomol Chem. 2017 Jul 21;15(27):5719-5730
pubmed: 28650492
Theranostics. 2020 Jan 1;10(1):151-165
pubmed: 31903112
Cancer Biother Radiopharm. 2004 Dec;19(6):706-15
pubmed: 15665617
Inorg Chem. 2019 Sep 16;58(18):12302-12310
pubmed: 31522510
J Immunol Methods. 1984 Aug 3;72(1):77-89
pubmed: 6086763
J Nucl Med. 2003 Aug;44(8):1271-81
pubmed: 12902418
Bioconjug Chem. 2019 Jun 19;30(6):1814-1820
pubmed: 31117346
Clin Cancer Res. 2006 Jun 15;12(12):3657-60
pubmed: 16778093
J Nucl Med. 2008 Jul;49(7):1114-31
pubmed: 18587088
Nat Protoc. 2010 Apr;5(4):739-43
pubmed: 20360768
Theranostics. 2018 Jul 30;8(16):4295-4304
pubmed: 30214621
Mol Cancer. 2018 Feb 19;17(1):45
pubmed: 29455668
J Nucl Med. 2010 Aug;51(8):1293-300
pubmed: 20660376
iScience. 2019 Mar 29;13:416-431
pubmed: 30903963
J Clin Oncol. 2017 Feb;35(4):412-420
pubmed: 27937096
Int J Cancer. 1995 Apr 10;61(2):286-8
pubmed: 7705960
Acc Chem Res. 2000 Nov;33(11):765-71
pubmed: 11087313
Angew Chem Int Ed Engl. 2019 Feb 11;58(7):1928-1933
pubmed: 30516314
Nat Rev Cancer. 2012 Jan 24;12(2):89-103
pubmed: 22270953
Chemistry. 2018 Nov 7;24(62):16472-16483
pubmed: 29956853
Chem Rev. 2006 Sep;106(9):3844-67
pubmed: 16967923
Clin Cancer Res. 2013 Sep 15;19(18):5068-78
pubmed: 23894056
J Nucl Med. 2019 May;60(5):691-695
pubmed: 30530830
Eur J Nucl Med Mol Imaging. 2017 Aug;44(8):1328-1336
pubmed: 28315949
J Nucl Med. 2018 Nov;59(11):1686-1691
pubmed: 29777004
Immunol Today. 1999 Sep;20(9):401-6
pubmed: 10532789
Eur J Nucl Med Mol Imaging. 2010 Feb;37(2):250-9
pubmed: 19763566
J Nucl Med. 2012 Oct;53(10):1592-600
pubmed: 22917884
Proc Natl Acad Sci U S A. 2013 Aug 6;110(32):E2987-96
pubmed: 23882082